SUMMARY
Tyrosine kinase (TK) activity in primary mononuclear blood cells (MNBC) derived from chronic
myelogenous leukemia (CML) patients in the chronic phase as well as from healthy donors was measured
by a sensitive time-resolved fluorescence method using the Delfia Tyrosine Kinase kit. The level of
phosphotyrosine was assessed in parallel by flow-cytometry. The experimental protocol for Delfia was
optimized using a K562 cell line. A large part (20 to 50%) of the fluorescence signal from K562 cells was
sensitive to Imatinib mesylate, an inhibitor of Bcr-Abl tyrosine kinase, which is currently the leading
drug in CML treatment. In primary MNBC, the direct contribution of Bcr-Abl itself to the signal was
low. However, a 48h treatment of MNBC with 5 microM Imatinib resulted in a significant reduction of the
observed TK activity (mean TK activity value: 56% of control) paralleled by a decrease in the
phosphotyrosine level in the CML group. Modification of TK activity by Imatinib was observed also in
the donor group. Imatinib mesylate thus probably affects cell signalization even in Bcr-Abl negative cells.
KEY WORDS
tyrosin-kinase activity; Imatinib; K562; primary blood cells; leukemia
REFERENCES
Appel S, Boehmler AM, Grunebach F et al.:
Imatinib mesylate affects the development and
function of dendritic cells generated from
CD34+ peripheral blood progenitor cells.
Blood 103:538-544, 2004.
Bartolovic K, Balabanov S, Hartmann U et al.:
Inhibitory effect of imatinib on normal
progenitor cells in vitro. Blood 103:523-529, 2004.
Baskaynak G, Kreuzer KA, Schwarz M et al.:
Squamous cutaneous epithelial cell carcinoma
in two CML patients with progressive disease
under imatinib treatment. Eur J Haematol
70:231-234, 2003.
Calabretta B, Perrotti D: The biology of CML
blast crisis. Blood 103:4010-4022, 2004.
Cwynarski K, Laylor R, Macchiarulo E et al.:
Imatinib inhibits the activation and
proliferation of normal T lymphocytes in vitro.
Leukemia 18:1332-1339, 2004.
Deininger MWN, Goldman JM, Lydon N, Melo
JV: The tyrosine kinase inhibitor
CGP57148B selectively inhibits the growth of
BCR-ABL-positive cells. Blood 90:3691-3698, 1997.
Deininger M, Buchdunger E, Druker BJ: The
development of imatinib as a therapeutic agent
for chronic myeloid leukemia. Blood
105:2640-2653, 2005.
Dewar AL, Cambareri AC, Zannettino ACW et
al.: Macrophage colony-stimulating factor
receptor c-fms is a novel target of imatinib.
Blood 105:3127-3132, 2005.
Dewar AL, Domaschenz RM, Doberty KV et
al.: Imatinib inhibits the in vitro development
of the monocyte/macrophage lineage from
normal human bone marrow progenitors.
Leukemia 17:1713-1721, 2003.
Dong R, Cwynarski K, Entwistle A et al.:
Dendritic cells from CML patients have altered
actin organization, reduced antigen processing
and impaired migration. Blood 101:3560-3567, 2003.
Druker BJ, Tamura S, Buchdunger E et al.:
Effects of a selective inhibitor of the Abl
tyrosine kinase on the growth of Bcr-Abl
positive cells. Nat Med 2:561-566, 1996.
Fang G, Kim CN, Perkins CL et al.:
CGP57148B (STI-571) induces differentiation
and apoptosis and sensitizes Bcr-Abl-positive
human leukemia cells to apoptosis due to
antileukemic drugs. Blood 96:2246-2253, 2000.
Ferrao PT, Frost MJ, Siah SP, Ashman LK:
Overexpression of P-glycoprotein in K562
cells does not confer resistance to the growth
inhibitory effects of imatinib (STI571) in vitro.
Blood 102:4499-4503, 2003.
Gambacorti-Passerini C, Le Coutre P, Mologni L
et al.: Inhibition of the ABL kinase activity
blocks the proliferation of BCR/ABL+
leukemic cells and induces apoptosis. Blood
Cells Mol Dis 23:380-394, 1997.
Grebenova D, Kuzelova K, Smetana K et al.:
Mitochondrial and endoplasmic reticulum
stress-induced apoptotic pathways are
activated by 5-aminolevulinic acid-based
photodynamic therapy in HL60 leukemia cells.
J Photochem Photobiol B, Biol 69:71-85, 2003.
Guo JQ, Lian JY, Xian YM et al.: BCR-ABL
Protein expression in peripheral blood cells of
chronic myelogenous leukemia patients
undergoing therapy. Blood 83:3629-3637, 1994.
Holtz MS, Slovak ML, Zhang F et al.: Imatinib
mesylate (STI571) inhibits growth of primitive
malignant progenitors in chronic myelogenous
leukemia through reversal of abnormally
increased proliferation. Blood 99:3792-3800, 2002.
Jacquel A, Herrant M, Legros L et al.: Imatinib
induces mitochondria-dependent apoptosis of
the Bcr-Abl positive K562 cell line and its
differentiation towards the erythroid lineage.
FASEB J 17:2160-2162, 2003.
Kantarjian H, Talpaz M, O´Brien S et al.: Highdose
imatinib therapy in newly diagnosed
Philadelphia chromosome-positive chronic
phase chronic myeloid leukemia. Blood
103:2873-2878, 2004.
Kawano T, Horiguchi-Yamada J, Saito S et al.:
Ectopic cyclin D1 expression blocks STI571-induced erythroid differentiation of K562 cells.
Leuk Res 28:623-629, 2004.
Kotaki M, Motoji T, Takanashi M et al.: Antiproliferative
effect of the abl tyrosine kinase
inhibitor STI571 on the P-glycoprotein
positive K562/ADM cell line. Cancer Lett
199:61-68, 2003.
Krystal GW: Imatinib mesylate (STI571) for
myeloid malignancies other than CML. Leuk
Res 28S1:S53-S59, 2004.
Kuzelova K, Grebenova D, Marinov I, Hrkal Z:
Fast apoptosis and erythroid differentiation
induced by Imatinib mesylate in JURL-MK1
cells. J Cell Biochem 95:268-280, 2005.
Le Coutre P, Kreuzer KA, Pursche S et al.:
Pharmacokinetics and cellular uptake of
imatinib and its main metabolite CGP74588.
Cancer Chemother Pharmacol 53:313-323, 2004.
Mahon FX, Deininger MWN, Schultheis B et
al.: Selection and characterization of BCR-ABL
positive cell lines with differential
sensitivity to the tyrosine kinase inhibitor
STI571: diverse mechanisms of resistance.
Blood 96:1070-1079, 2000.
Mahon FX, Belloc F, Lagarde V et al.: MDR1
gene overexpression confers resistance to
imatinib mesylate in leukemia cell line models.
Blood 101:2368-2373, 2003.
Manley PW, Cowan-Jacob SW, Buchdunger E
et al.: Imatinib: a selective tyrosine kinase
inhibitor. Eur J Cancer 38:S19-S27, 2002.
Mattiuzzi GN, Cortes JE, Talpaz M et al.:
Development of Varicella-Zoster virus
infection in patients with chronic myelogenous
leukemia treated with imatinib mesylate. Clin
Cancer Res 9:976-980, 2003.
Mohty M, Jourdan E, Mami NB et al.: Imatinib
and plasmacytoid dendritic cell function in
patients with chronic myeloid leukemia. Blood
103:4666-4668, 2004.
Mukai M, Che XF, Furukawa T et al.: Reversal
of the resistance to STI571 in human chronic
myelogenous leukemia K562 cells. Cancer Sci
94:557-563, 2003.
Rodley P, McDonald M, Price B et al.:
Comparative genomic hybridization reveals
previously undescribed amplifications and
deletions in the chronic myeloid leukemiaderived
K-562 cell line. Genes Chromosomes
Cancer 19:36-42, 1997.
Sawyers C.L., Hochhaus A., Feldman E. et al.:
Imatinib induces hematological and
cytogenetic responses in patients with chronic
myelogenous leukemia in myeloid blast crisis:
results of a phase II study. Blood 99:3530-3539,
2002.
Shaul Y, Ben-Yehoyada M: Role of c-Abl in the
DNA damage stress response. Cell Res 15:33-35, 2005.
Steelman LS, Pohnert SC, Shelton JG et al.:
JAK/STAT, RaF/MEK/ERK, PI3K/Akt and
BCR-ABL in cell cycle progression and
leukemogenesis. Leukemia 18:189-218, 2004.
Taieb J, Maruyama K, Borg C et al.: Imatinib
mesylate impairs Flt3L-mediated dendritic cell
expansion and antitumor effects in vivo. Blood
103:1966-1967, 2004.
Takahashi N, Miura I, Saitoh K, Miura AB:
Lineage involvement of stem cells bearing the
Philadelphia chromosome in chronic myeloid
leukemia in the chronic phase as shown by a
combination of fluorescence-activated cell
sorting and fluorescence in situ hybridization.
Blood 92:4758-4763, 1998.
Talpaz M, Silver RT, Druker BJ et al.: Imatinib
induces durable hematologic and cytogenetic
responses in patients with accelerated phase
chronic myeloid leukemia: results of a phase 2
study. Blood 99:1928-1937, 2002.
Traina F, Carvalheira JBC, Saad MJA et al.:
BCR-ABL binds to IRS-1 and IRS-1
phosphorylation is inhibited by imatinib in
K562 cells. FEBS Lett 535:17-22, 2003.
Weisberg E, Griffin JD: Mechanism of resistance
to the ABL tyrosine kinase inhibitor STI571 in
BCR/ABL-transformed hematopoietic cell
lines. Blood 95:3498-3505, 2000.
Wu SQ, Voelkerding KV, Sabatini L et al.:
Extensive amplification of bcr/abl fusion genes
clustered on three marker chromosomes in
human leukemic cell line K-562. Leukemia 9:858-862, 1995.
|
CITED
Kuzelova K, Pluskalova M, Brodska B, Otevrelova P, Elknerova K, Grebenova D, Hrkal Z: Suberoylanilide Hydroxamic Acid (SAHA) at Subtoxic Concentrations
Increases the Adhesivity of Human Leukemic Cells to Fibronectin. J Cell Biochem 109:184-195, 2010.
|
